3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
44
Squamous Cell Carcinoma of Head and Neck
23
Carcinoma, Non-Small-Cell Lung
23
Head and Neck Neoplasms
13
Pancreatic Neoplasms
11
Neoplasm Metastasis
10
Carcinoma, Squamous Cell
8
Neoplasms
7
Lung Neoplasms
7
Colonic Neoplasms
7
Rectal Neoplasms
6
Esophageal Neoplasms
5
Carcinoma
5
Recurrence
4
Carcinoma, Renal Cell
4
Stomach Neoplasms
3
Neoplasms, Squamous Cell
3
Hereditary Sensory and Autonomic Neuropathies
3
Glioblastoma
3
Gastrointestinal Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Colorectal Cancer Metastatic
3
Breast Neoplasms
3
Tongue Neoplasms
2
Sarcoma
2
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Melanoma
2
Glioma
2
Interventions
Irinotecan
3
5,10-methylenetetrahydrofolic acid
2
tislelizumab
1
spartalizumab
1
repotrectinib
1
pralsetinib
1
palbociclib
1
encorafenib
1
Pemetrexed
1
Levoleucovorin
1
Leucovorin
1
KRN-330
1
Immune Checkpoint Inhibitors
1
Imatinib Mesylate
1
Gemcitabine
1
Flucytosine
1
Everolimus
1
Cisplatin
1
Cetuximab
1
Capecitabine
1
Ascorbic Acid
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Digestive System Neoplasms
×
Cetuximab
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled